For the use only of Registered Medical Practitioners or a Hospital or a Laboratory ACTIFED DM COUGH SYRUP
|
|
- Hilary Stanley
- 5 years ago
- Views:
Transcription
1 For the use only of Registered Medical Practitioners or a Hospital or a Laboratory ACTIFED DM COUGH SYRUP Triprolidine Hydrochloride and Dextromethorphan Hydrobromide Syrup QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml contains: Triprolidine Hydrochloride IP 1.25 mg Dextromethorphan Hydrobromide IP 10.0 mg in a flavoured syrup base containing Menthol IP Colour: Ponceau 4R PHARMACEUTICAL FORM Syrup for oral administration. CLINICAL PARTICULARS Therapeutic Indications ACTIFED DM COUGH SYRUP is indicated for symptomatic relief of persistent, dry and irritating cough associated with respiratory tract disorders. Posology and Method of Administration Consider re-evaluation of patient if symptoms persist more than 7 days. Adults and children aged 12 years and over Oral 10 ml every 5 hours. Maximum daily dose 40 ml (Dextromethorphan 80 mg and Triprolidine 10 mg). Children aged 6-11 years Oral 5 ml every 5 hours. Maximum daily dose 20 ml (Dextromethorphan 40 mg and Triprolidine 5 mg). Children aged 2-6 years Oral 2.5 ml every 5 hours. Maximum daily dose 10 ml (Dextromethorphan 20 mg and Triprolidine 2.5 mg). Children under 2 years of age Not recommended in children under 2 years of age. 1
2 Elderly The elderly are more likely to experience the neurological anticholinergic effects of triprolidine, including confusion, and to develop paradoxical excitation (see Special Warnings and Special Precautions for Use). Hepatic impairment Triprolidine is eliminated primarily by hepatic metabolism therefore consideration should be given to reducing the dose in those with severe hepatic impairment. Renal impairment Caution should be exercised when administering ACTIFED DM COUGH SYRUP to patients with severe renal impairment. Do not exceed the stated dose. Keep out of the reach and sight of children. Contraindications ACTIFED DM COUGH SYRUP is contraindicated in patients: Who are hypersensitive to any of the ingredients. With, or at risk of developing, respiratory failure (e.g. those with chronic obstructive airways disease or pneumonia, or during an asthma attack or an exacerbation of asthma). Who are taking or have taken monoamine oxidase inhibitors (MAOIs) in the last two weeks. Special Warnings and Special Precautions for Use Caution should be exercised while prescribing ACTIFED DM COUGH SYRUP in patients with: Chronic or persistent cough, such as occurs with asthma and emphysema, chronic bronchitis, or where cough is accompanied by excessive secretions. Severe hepatic impairment. Severe renal impairment. Concomitant use of a selective serotonin reuptake inhibitor (SSRI) or tricyclic antidepressant (see Interaction with Other Medicaments and Other Forms of Interaction). Cases of dextromethorphan abuse have been reported. Caution is particularly recommended for adolescents and young adults as well as in patients with a history of drug abuse or psychoactive substances. Dextromethorphan is metabolised by hepatic cytochrome P450 2D6. The activity of this enzyme is genetically determined. About 10% of the general population are poor metabolisers of CYP2D6. Poor metabolisers and patients with concomitant use of CYP2D6 inhibitors may 2
3 experience exaggerated and/or prolonged effects of dextromethorphan. Caution should therefore be exercised in patients who are slow metabolizers of CYP2D6 or use CYP2D6 inhibitors ACTIFED DM Cough Syrup should be used cautiously in patients with asthma, bronchitis, chronic obstructive pulmonary disease (COPD), or emphysema. Thickened bronchial secretions that aggravate these conditions may result from the anticholinergic activity of H1- antagonists. ACTIFED DM Cough Syrup use may be possible in patients with these illnesses, particularly if thick bronchial secretions are not a primary component of the illness. The anticholingeric effects of triprolidine may worsen symptoms in patients with symptomatic prostatic hypertrophy or bladder obstruction. Use ACTIFED DM Cough Syrup conservatively in patients with cardiac disease or hypertension. Quinidine-like local anesthetic and anticholingeric properties of H1-antagonists may produce adverse cardiovascular effects such as tachycardia, ECG changes, or arrhythmias. Closed-angle glaucoma may be exacerbated by ACTIFED DM Cough Syrup use. The anticholinergic effects of H1-antagonists may increase intraocular pressure, which can precipitate an acute attack of glaucoma. Triprolidine may also cause dry eyes or blurred vision, which can impact the ability of patients to wear contact lenses. ACTIFED DM Cough Syrup should be used with caution in geriatric patients, as they may be more susceptible to adverse anticholinergic effects. Other anticholinergic medications, may intensify these effects, particularly in the elderly. Existing medical conditions and pharmacotherapy should be considered before using sedating antihistamines in the older adult. If administered, antihistamines should be used in the smallest possible dose in individuals who are susceptible to anticholinergic side effects or who are receiving other medications with anticholinergic properties. Anticholinergics may cause excessive sedation, confusion, cognitive impairment, distress, dry mouth, constipation, and urinary retention. Many of these effects may lead to other adverse consequences, such as falls. Use H1-antagonists such as triprolidine with caution in patients with pyloroduodenal GI obstruction or stenosing peptic ulcer disease. Anticholinergic activity may contribute to delayed gastric emptying, which may produce greater GI occlusion. Triprolidine is extensively metabolized by the liver. The metabolism of triprolidine may be reduced in patients with hepatic impairment. Patients with pre-existing hepatic disease may require dosage adjustments. Liver function tests and adverse effects should be monitored. Antihistamines such as triprolidine may exacerbate hyperthyroidism and cause tachycardia. Use ACTIFED DM Cough Syrup with caution in this patient population. Patients should be monitored for adverse effects. ACTIFED DM Cough Syrup may cause excitability and CNS stimulation in children, infants, and neonates. Cyanosis and apnea may also occur in infants and neonates who receive H1- antagonists. Patient should be reassessed if the cough persists despite treatment with ACTIFED DM COUGH SYRUP or if it is accompanied by high fever, skin rash or persistent headache. 3
4 Concomitant use of other cough and cold medicines should be avoided. Concomitant use of alcohol should be avoided. Do not exceed the maximum recommended dose or frequency of dosing. Precautions for specific ingredients ACTIFED DM COUGH SYRUP contains Sorbitol - Patients with rare hereditary problems of fructose intolerance should not take this medicine. ACTIFED DM COUGH SYRUP contains methylparaben and propylparaben which may cause allergic reactions (possibly delayed). Interaction with Other Medicaments and Other Forms of Interaction The use of dextromethorphan with, or within two weeks of taking monoamine oxidase inhibitors (MAOIs) should be avoided as severe reactions including serotonin syndrome have been reported (see Contraindications). Concomitant use of dextromethorphan with selective serotonin re-uptake inhibitors (SSRIs) or tricyclic antidepressants may result in serotonin syndrome with changes in mental status, hypertension, restlessness, myoclonus, hyperreflexia, diaphoresis, shivering and tremor (see Special Warnings and Special Precautions for Use). Dextromethorphan is metabolized by CYP2D6 and has an extensive first pass metabolism. Concomitant use of potent CYP2D6 enzyme inhibitors can increase the dextromethorphan concentrations in the body to levels multifold higher than normal. This increases the patient's risk for toxic effects of dextromethorphan (agitation, confusion, tremor, insomnia, diarrhoea and respiratory depression) and development of serotonin syndrome. Potent CYP2D6 enzyme inhibitors include fluoxetine, paroxetine, quinidine and terbinafine. In concomitant use with quinidine, plasma concentrations of dextromethorphan have increased up to 20fold, which has increased the CNS adverse effects of the agent. Amiodarone, flecainide and propafenone, sertraline, bupropion, methadone, cinacalcet, haloperidol, perphenazine and thioridazine also have similar effects on the metabolism of dextromethorphan. If concomitant use of CYP2D6 inhibitors and dextromethorphan is necessary, the patient should be monitored and the dextromethorphan dose may need to be reduced. Concomitant use of dextromethorphan and alcohol may increase the CNS depressant effects of both drugs. Concurrent use of triprolidine and hypnotics, sedatives or anxiolytics may potentiate drowsiness [See Special Warnings and Special Precautions for Use]. Concurrent use of alcohol may have a similar effect [See Special Warnings and Special Precautions for Use]. The anticholinergic effects of triprolidine are intensified by MAOIs [see Contraindications]. Concurrent use of bupropion and agents lowering seizure threshold may result in lower seizure threshold. 4
5 Pregnancy and Lactation Fertility There is no experience of the effect of ACTIFED DM COUGH SYRUP on human fertility. There is insufficient information available to determine whether dextromethorphan has teratogenic potential. In rats and rabbits, systemic administration of triprolidine up to 75 times the human daily dosage did not produce teratogenic effects. No studies have been conducted in animals to determine whether triprolidine has potential to impair fertility. Pregnancy Although dextromethorphan and triprolidine have been in widespread use for many years without apparent ill consequence, there are no specific data on their use during pregnancy. Caution should therefore be exercised by balancing the potential benefit of treatment to the mother against any possible hazards to the developing foetus. Lactation Triprolidine is excreted in breast milk in small amounts but the effect of this on breast-fed infants is not known. It is not known whether dextromethorphan or its metabolites are excreted in breast milk. Caution should be exercised while prescribing ACTIFED DM COUGH SYRUP to lactating women. Effects on Ability to Drive and Use Machines Dextromethorphan may cause drowsiness and dizziness. The anticholinergic properties of triprolidine may cause drowsiness, dizziness, blurred vision and psychomotor impairment in some patients which may seriously affect ability to drive and use machinery. Those affected should not drive or operate machinery. Undesirable Effects The following adverse events have been reported for the ingredients of ACTIFED DM COUGH SYRUP. Dextromethorphan Clinical Data The following adverse events have been observed in clinical trials with dextromethorphan and are likely to represent uncommon adverse reactions to dextromethorphan (i.e. occurring in 1/1,000 to <1/100 patients). Adverse reactions are listed below by MedDRA System Organ Class. Nervous system disorders drowsiness; dizziness. Gastrointestinal disorders gastrointestinal disturbance; nausea; vomiting; abdominal discomfort. 5
6 Post Marketing Data Adverse reactions identified during post-marketing use are listed below. As these reactions are reported voluntarily from a population of uncertain size, the frequency of these reactions is unknown but likely to be rare or very rare (occurring in < 1/1000 patients). Nervous system disorders Serotonin syndrome. Serotonin syndrome (with changes in mental status, restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, tremor and hypertension) has been reported when dextromethorphan has been taken concurrently with MAOIs or serotonergic drugs such as SSRIs (see Contraindications and Interaction with Other Medicaments and Other Forms of Interaction). Skin and subcutaneous disorders allergic reactions (e.g. rash, urticaria, angioedema) Triprolidine Clinical Trial Data Adverse events from historical clinical trial data are both infrequent and from small patient exposure. Post Marketing Data The following adverse reactions have been reported with triprolidine hydrochloride: Psychiatric disorders Unknown: paradoxical excitation*, confusion**, nightmares***, hallucinations*** * Children and the elderly are more susceptible to paradoxical excitation (e.g. increased energy, restlessness, nervousness). ** The elderly are more prone to confusion. ***Hallucinations and nightmares have been reported mainly in children Nervous System Disorders Very common ( 1/10): sedation, drowsiness Common ( 1/100 to <1/10): disturbance in attention, abnormal coordination, dizziness Eye disorders Unknown: blurred vision Respiratory, thoracic and mediastinal disorders Unknown: thickening of bronchial secretions Gastrointestinal disorders 6
7 Common ( 1/100 to <1/10): dry mouth, nose and throat Unknown: gastrointestinal disturbance including nausea, vomiting Skin and subcutaneous tissue disorders Unknown: rash, urticaria Renal and urinary disorders Unknown: urinary retention Overdose Symptoms and Signs Dextromethorphan Dextromethorphan overdose is likely to result in effects similar to those listed under Undesirable Effects. Following large overdoses, additional symptoms may include excitation, mental confusion, restlessness, nervousness and irritability, stupor, ataxia, dystonia, hallucinations, psychosis and respiratory depression. Triprolidine Triprolidine overdose is likely to result in effects similar to those listed under Undesirable Effects. Additional symptoms may include ataxia, weakness, respiratory depression, dryness of the skin and mucous membranes, hyperpyrexia, tremor, psychosis, convulsions, tachycardia and arrhythmias. Treatment For dextromethorphan overdose: Supportive and symptomatic care should be provided as required. If overdose is severe, naloxone may be helpful, particularly for patients with respiratory depression. For triprolidine overdose: Treatment should be supportive and directed towards specific symptoms. PHARMACOLOGICAL PROPERTIES Pharmacodynamic Properties Dextromethorphan Dextromethorphan has an antitussive action. It controls cough spasms by depressing the medullary cough centre. Dextromethorphan is a cough suppressant which has a central action on the cough centre of the medulla. Triprolidine hydrochloride 7
8 Triprolidine hydrochloride is an antihistamine which acts as a histamine H1- receptor antagonist. Triprolidine belongs to the group of alkylamines (propylamine) and has minimal anticholinergic effect. Pharmacokinetic Properties Dextromethorphan Absorption Dextromethorphan hydrobromide is well absorbed from the gastrointestinal tract. Distribution Due to extensive pre-systemic metabolism by the liver, detailed analysis of the distribution of orally administered dextromethorphan is not possible. Metabolism Dextromethorphan undergoes rapid and extensive first-pass metabolism in the liver after oral administration. Genetically controlled O-demethylation (CYD2D6) is the main determinant of dextromethorphan pharmacokinetics in human volunteers. It appears that there are distinct phenotypes for this oxidation process resulting in highly variable pharmacokinetics between subjects. Unmetabolised dextromethorphan, together with the three demethylated morphinan metabolites dextrorphan (also known as 3-hydroxy-Nmethylmorphinan), 3- hydroxymorphinan and 3-methoxymorphinan have been identified as conjugated products in the urine. Dextrorphan, which also has antitussive action, is the main metabolite. In some individuals metabolism proceeds more slowly and unchanged dextromethorphan predominates in the blood and urine. Elimination Dextromethorphan and its metabolites are excreted in urine for up to 50% of the ingested dose at 24 hours. Only a very small quantity of unchanged dextromethorphan is found in the urine. The elimination half-lives of dextromethorphan vary greatly depending on the dose administered and on the patient s CYP2D6 phenotype. In one study, the half-life of the elimination phase of dextromethorphan was on average approximately 7 times higher in some subjects. The half-life of main metabolite dextrorphan is hours. Triprolidine hydrochloride Absorption The maximum effect of oral administration is observed 60 minutes after taking and persists for approximately five hours. Peak plasma concentration (Cmax) is observed two hours (Tmax) after administration and the plasma half-life is approximately 3.2 hours. Triprolidine is metabolised 8
9 by the hepatic microsomes. Approximately 1% of the dose administered appears in the urine in unaltered form. Distribution No relevant data available. Metabolism Metabolised by the hepatic microsomes. Approximately 1% of the dose administered appears in the urine in unaltered form. Elimination No relevant information. Preclinical Safety Data No relevant data available. PHARMACEUTICAL PARTICULARS List of Excipients Sorbitol 70% solution, Glycerin, Propylene Glycol, Methylparaben, Propylparaben, Sodium Chloride, Sodium Citrate, Menthol, Sodium saccharin, Ponceau 4R ISI (*), Flavour Mixed Fruit RSV IFF, Purified water Incompatibilities No incompatibilities have been identified. Shelf Life The expiry date is indicated on the label and packaging. Special Precautions for Storage Store in a well closed container at temperatures not exceeding 30ºC. Protect from direct sunlight. Keep out of reach of children. Nature and Specification of Container Amber PET bottle with a measure cup. Instructions for Use / Handling. There are no special requirements for use or handling of the product. For further information please contact: 9
10 GlaxoSmithKline Pharmaceuticals Limited. Registered Office Dr. Annie Besant Road, Worli Mumbai , India. Trade marks are owned by or licensed to the GSK group of companies Version: ACTDM/PI/IN/2018/01 dated 06 May 2018 Adapted from: Dextromethorphan GDS (Cx) version 04 dated 20-July-2017 Phenylephrine Hydrochloride & Triprolidine Hydrochloride GDS (Cx) version 01 dated 22 Dec Multi-Action Actifed Dry Coughs SPC last updated on 20-Dec-2016, date of revision of text 07-Dec-2016 Triprolidine Available from Accessed on 27-Feb
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory PIRITON CS
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory PIRITON CS Chlorpheniramine Maleate with Dextromethorphan Hydrobromide Syrup QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory DILO DX TM SYRUP
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory DILO DX TM SYRUP Chlorpheniramine Maleate with Dextromethorphan Hydrobromide Syrup QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationPRODUCT INFORMATION. Benadryl* for the Family Nightime Oral Liquid
Product description PRODUCT INFORMATION Benadryl* for the Family Nightime Oral Liquid Each 5 ml of Benadryl* Nightime oral liquid contains dextromethorphan hydrobromide 10 mg and diphenhydramine hydrochloride
More informationPRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.
PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine
More informationPackage Insert. Clistin Dry. 24 hours.
Package Insert Clistin Dry Product Summary 1. Name of the medicinal product Clistin Dry 2. Qualitative and quantitative composition Dextromethorphan Hbr 10 mg Chlorpheniramine Maleate 2 mg Phenylephrine
More informationPANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other.
Product description PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other. Ingredients Active Ingredients: Paracetamol
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME Sudomyl, Tablet, 60 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Pseudoephedrine Hydrochloride 60mg Excipient(s) with known effect For the full
More informationBenylin Children's Coughs & Colds 5mg/0.625mg per 5ml Syrup dextromethorphan, triprolidine
Benylin Children's Coughs & Colds 5mg/0.625mg per 5ml Syrup dextromethorphan, triprolidine This medicine is used to help relieve children s dry cough and cold symptoms. This medicine is for use by children
More informationNausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.
Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine
More informationNEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.
1. PRODUCT NAME ACUPAN 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nefopam hydrochloride 30 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
More informationDATA SHEET. Paracetamol (BP) 500mg, Dextromethorphan Hydrobromide (BP) 15mg and Phenylephrine Hydrochloride (BP) 5mg
PANADOL COLD & FLU RELIEF + COUGH CAPLETS DATA SHEET Paracetamol (BP) 500mg, Dextromethorphan Hydrobromide (BP) 15mg and Phenylephrine Hydrochloride (BP) 5mg Presentation Blue capsule-shaped tablets (caplets)
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Benylin Dry Coughs Syrup Diphenhydramine hydrochloride 14 mg/5ml Dextromethorphan hydrobromide 6.5 mg/5ml Levomenthol 2 mg/5ml Read all of this leaflet carefully
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More informationSANDOMIGRAN (pizotifen malate)
SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.
More informationTOULARYNX DEXTROMETHORPHAN FORTE 3 mg/ml, syrup Dextromethorphan HBr monohydrate
TOULARYNX DEXTROMETHORPHAN FORTE 3 mg/ml, syrup Dextromethorphan HBr monohydrate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Unichem Allergy Relief Antihistamine Tablets Moss Pharmacy Allergy Relief Antihistamine Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Otrivin Menthol (without preservative) 1.0 mg/ml nasal spray, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 1.0 mg
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationNAPHCON-A Eye Drops naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%.
NEW ZEALAND DATA SHEET 1. PRODUCT NAME NAPHCON-A Eye Drops naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Naphcon-A contains naphazoline hydrochloride
More informationSalapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.
Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT WICK Chesty Cough Syrup 200 mg/15 ml 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 15 ml syrup contains 200 mg guaifenesin. Each ml syrup
More informationPRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets
PRODUCT INFORMATION SUDAFED Sinus 12 Hour Relief Tablets NAME OF THE MEDICINE Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 DESCRIPTION SUDAFED Sinus 12 Hour Relief prolonged-release tablets
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory COBADEX SYRUP
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory COBADEX SYRUP Vitamin B12-B Complex Liquid QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml (one teaspoonful) contains:
More informationM0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:
M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered
More information1. NAME OF THE MEDICINAL PRODUCT. Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE MEDICINAL PRODUCT Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Oxymetazoline hydrochloride 0.5 mg/ml 1 spray (50 l) contains approximately 25
More informationMigraleve, Migraleve Pink and Migraleve Yellow Product Information
Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible
More informationPRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets
PRODUCT INFORMATION Sudafed* Sinus Day + Night Relief Tablets Product description Sudafed* Sinus Day + Night Relief tablets contain two separate formulations: day tablets and night tablets. Each Sudafed*
More informationFor the use only of a Registered Medical Practitioner or a Hospital or a Laboratory. Light Liquid Paraffin and White Soft Paraffin Cream
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory OILATUM CREAM / KIDS CREAM Light Liquid Paraffin and White Soft Paraffin Cream QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationTRAPADOL INJECTION FOR I.V./I.M. USE ONLY
TRAPADOL INJECTION FOR I.V./I.M. USE ONLY Composition : Each 2ml. contains : Tramadol Hydrochloride I.P. Water for injection I.P. 100mg. q.s. CLINICAL PHARMACOLOGY : Pharmacodynamics Tramadol is a centrally
More informationPRODUCT INFORMATION. Codral* Original Cold & Flu + Cough Day & Night Capsules
PRODUCT INFORMATION Codral* Original Cold & Flu + Cough Day & Night Capsules Description Codral* Original Cold & Flu + Cough Day & Night capsules contain two separate formulations: day capsules and night
More informationPRODUCT INFORMATION. Active ingredients Chemical structure CAS Registry Number. Paracetamol
PRODUCT INFORMATION PANADOL FLU STRENGTH DAY & NIGHT CAPLETS NAME OF THE MEDICINE Active ingredients Chemical structure CAS Registry Number Paracetamol 103-90-2 Phenylephrine Hydrochloride 61-76-7 Dextromethorphan
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine
More informationPRODUCT INFORMATION. (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate
NORGESIC Orphenadrine citrate and paracetamol PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: CAS number: 4682-36-4 Chemical structure: Orphenadrine citrate (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine
More informationPRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets
PRODUCT INFORMATION Sudafed* Sinus Day + Night Relief Tablets Name of the Medicine Paracetamol CAS 2 Registry Number: 103-90-2 Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 Triprolidine
More informationLevocetirizine dihydrochloride
INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5
More informationPRODUCT INFORMATION. Parke Davis* Day & Night Original Cough Cold & Flu Capsules
PRODUCT INFORMATION Parke Davis* Day & Night Original Cough Cold & Flu Capsules Product description Parke Davis* Day & Night Original Cough Cold & Flu capsules contain two separate formulations: day capsules
More informationPRODUCT INFORMATION. Sudafed* Sinus + Allergy & Pain Relief Tablets
PRODUCT INFORMATION Sudafed* Sinus + Allergy & Pain Relief Tablets Name of the Medicine Paracetamol CAS 2 Registry Number: 103-90-2 Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 Triprolidine
More informationNEW ZEALAND DATASHEET
NEW ZEALAND DATASHEET COLDREX HOT REMEDY COLD & FLU HOT LEMON Powder for Oral Solution Paracetamol (BP) 1000mg/sachet Presentation Pale yellow, free flowing heterogeneous powder with and odour of lemon
More informationTo report SUSPECTED ADVERSE REACTIONS, contact Avadel Pharmaceuticals (USA), Inc. at or FDA at FDA-1088 or
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KARBINAL ER safely and effectively. See full prescribing information for KARBINAL ER. Karbinal ER
More informationAVIOMARIN 50 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER AVIOMARIN 50 mg tablets DIMENHYDRINATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationPANADOL SINUS DAY & NIGHT TABLETS PRODUCT INFORMATION
Product description PANADOL SINUS DAY tablet is a white, film-coated capsule-shaped tablet with flat edges, front and back faces marked with DAY. PANADOL SINUS NIGHT tablet is a white, film-coated round
More informationPANADOL COLD & FLU MAX HOT LEMON Powder for Oral Solution DATA SHEET
PANADOL COLD & FLU MAX HOT LEMON Powder for Oral Solution Paracetamol (BP) 1000mg/sachet DATA SHEET Presentation Pale yellow, free flowing heterogeneous powder with and odour of lemon Indications Fast,
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory ZODERM E CREAM. Oxiconazole Nitrate Cream
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory ZODERM E CREAM Oxiconazole Nitrate Cream QUALITATIVE AND QUANTITATIVE COMPOSITION ZODERM E CREAM contains: Oxiconazole
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationDATA SHEET. Proprietary (Trade) Name: COLDREX PE Phenylephrine Cold & Flu Night & Day
COLDREX PE PHENYLEPHRINE COLD &FLU NIGHT & DAY CAPLETS DATA SHEET Proprietary (Trade) Name: COLDREX PE Phenylephrine Cold & Flu Night & Day Active ingredients: DAY caplet Paracetamol (BP) 500 mg/caplet
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1. TRADE NAME OF THE MEDICINAL PRODUCT Mebeverine Tablets BP 135 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 135 mg of Mebeverine Hydrochloride
More informationPackage Insert. D-Bright
Package Insert D-Bright Product Summary 1. Name of the medicinal product D-Bright 2. Qualitative and quantitative composition Each ml contains Cholecalciferol (Vitamin D3) IP 400 IU in a flavoured syrupy
More informationPARACOD Tablets (Paracetamol + Codeine phosphate)
Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zaditen 0.25 mg/ml, eye drops, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains 0.345 mg ketotifen fumarate corresponding
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory KEMADRIN TABLETS. Procyclidine Tablets IP 2.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory KEMADRIN TABLETS Procyclidine Tablets IP 2.5 mg and 5 mg QUALITATIVE AND QUANTITATIVE COMPOSITION KEMADRIN TABLETS 2.5
More informationPRODUCT INFORMATION LEAFLET
PRODUCT INFORMATION LEAFLET 1. Product Name Brand Name: Crocin Cold & Flu Max Generic Name: Paracetamol, Caffeine and Phenylephrine Hydrochloride Tablets 2. Qualitative & Quantitative Composition Each
More information3 PHARMACEUTICAL FORM Coated tablet Round, white to off-white, sugar coated tablets, plain on both sides.
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mebeverine hydrochloride 135 mg coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains 135 mg of mebeverine
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fexofenadine hydrochloride 180 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 180mg
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. EPHEDRINE HCl STEROP 10mg/ml EPHEDRINE HCl STEROP 50mg/ml Solution for injection. Ephedrine Hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER EPHEDRINE HCl STEROP 10mg/ml EPHEDRINE HCl STEROP 50mg/ml Solution for injection Ephedrine Hydrochloride Read all of this leaflet carefully before you start using
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationQualitative and Quantitative Composition
DATA SHEET KEMADRIN Tablets Procyclidine Hydrochloride 5 mg Tablets Qualitative and Quantitative Composition White, round, biconvex tablets, one face with a break line and coded KT above the break line
More informationPharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:
0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology
More information100 ml of the syrup contain 825 mg of ivy leaf dry extract (Hedera helix L., folium) ( 4-8:1). Extraction solvent: ethanol 30% (m/m).
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Hedussin syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 100 ml of the syrup contain 825 mg of ivy leaf dry extract (Hedera helix L.,
More informationCHILDREN S PANADOL COLOURFREE SUSPENSION PANADOL SUPPOSITORIES 125 MG PANADOL SUPPOSITORIES 250 MG DATA SHEET. Proprietary (Trade) Name: PANADOL
CHILDREN S PANADOL COLOURFREE SUSPENSION PANADOL SUPPOSITORIES 125 MG PANADOL SUPPOSITORIES 250 MG DATA SHEET Proprietary (Trade) Name: PANADOL Active ingredient: Paracetamol (BP) 120 mg/5ml (Children
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR:
Core Safety Profile Active substance: Clotiazepam Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg P-RMS: BE/H/PSUR/0002/002 Date of FAR: 16.06.2011 4.3 Contraindications is contraindicated
More informationIPRAVENT Respules/Respirator solution (Ipratropium bromide)
Published on: 19 Sep 2014 IPRAVENT Respules/Respirator solution (Ipratropium bromide) Composition IPRAVENT Respules Each 2 ml contains: Ipratropium Bromide BP equivalent to Ipratropium Bromide (anhydrous)
More informationPackage Insert. Constipeg
Package Insert Constipeg Product Summary 1. Name of the medicinal product Constipeg sachets 2. Qualitative and quantitative composition Each 13.7 g sachet contains PEG polyethylene glycol (macrogol) USNF
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 PRODUCT NAME TROPISETRON-AFT tropisetron hydrochloride (equivalent to 2 mg or 5 mg tropisetron) per ampoule. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 1 mg of tropisetron 1 2 ml ampoule
More informationActive Ingredients: Chlorpheniramine maleate 1,25 mg and phenylephrine hydrochloride
SCHEDULING STATUS S2 PROPRIETARY NAME AND DOSAGE FORM DEMAZIN Syrup COMPOSITION Each 5 ml contains: Active Ingredients: Chlorpheniramine maleate 1,25 mg and phenylephrine hydrochloride 2,5 mg. Inactive
More informationParacetamol, codeine phosphate hemihydrate and promethazine hydrochloride.
AUSTRALIAN PRODUCT INFORMATION, PAINSTOP NIGHT-TIME PAIN RELIEVER (PARACETAMOL 120MG IN 5ML,CODEINE PHOSPHATE HEMIHYDRATE 5MG IN 5ML AND PROMETHAZINE HYDROCHLORIDE 6.5MG IN 5ML) 1. NAME OF THE MEDICINE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 6 1. Name of the Medicinal Product Cycloserine 250mg Capsules 2. Qualitative and Quantitative Composition Each hard capsule contains: Cycloserine 250 mg For
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:
Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension
More informationPRODUCT INFORMATION PANADOL COLD & FLU MAX HOT LEMON POWDER NAME OF THE MEDICINE. Chemical structure: CAS 2 Registry Number: DESCRIPTION
PRODUCT INFORMATION PANADOL COLD & FLU MAX HOT LEMON POWDER NAME OF THE MEDICINE Active ingredient: Paracetamol Chemical structure: CAS 2 Registry Number: 103-90-2 DESCRIPTION Paracetamol is a white, crystalline
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET VERGO 16 1. Product Name Vergo 16, 16 mg, tablet. 2. Qualitative and Quantitative Composition Each tablet contains 16 mg of betahistine dihydrochloride. For the full list of excipients,
More informationPRESCRIBING INFORMATION WITH CONSUMER INFORMATION MYDRIACYL. tropicamide ophthalmic solution, USP. 0.5% and 1% w/v.
PRESCRIBING INFORMATION WITH CONSUMER INFORMATION Pr MYDRIACYL tropicamide ophthalmic solution, USP 0.5% and 1% w/v Anticholinergic Alcon Canada Inc. 2665 Meadowpine Blvd. Mississauga, ON L5N 8C7 www.alcon.ca
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Prostasan soft capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 320 mg of extract (as soft extract) from Serenoa
More informationCore Safety Profile. Pharmaceutical form(s)/strength: 5mg/ml and 25 mg/ml, Solution for injection, IM/IV FI/H/PSUR/0010/002 Date of FAR:
Core Safety Profile Active substance: Esketamine Pharmaceutical form(s)/strength: 5mg/ml and 25 mg/ml, Solution for injection, IM/IV P-RMS: FI/H/PSUR/0010/002 Date of FAR: 29.05.2012 4.3 Contraindications
More informationPackage leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride
Package leaflet: Information for the patient / / 30 mg/5 ml syrup Ambroxol hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Flavamed Hustensaft 15 mg/5 ml oral solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of oral solution contains 3 mg ambroxol
More informationActive ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg
Name Primperan 10 mg / 2 ml Metoclopramide hydrochloride anhydrous Solution for I.M. or I.V. injection (Ampoules) Composition Each 2 ml ampoule contains: Active ingredients: Metoclopramide Hydrochloride.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Omnilax 10 g powder for oral solution, sachet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One sachet contains 10 g of macrogol 4000.
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Panadol Baby 120 mg/5 ml, Oral Suspension. Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml spoonful of suspension contains paracetamol
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Citanest with Octapressin Dental 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Prilocaine Hydrochloride 30 mg (54 mg/1.8
More informationVENTOLIN RESPIRATOR SOLUTION
VENTOLIN RESPIRATOR SOLUTION Salbutamol QUALITATIVE AND QUANTITATIVE COMPOSITION VENTOLIN Respirator Solution contains 5mg salbutamol, as sulphate, per ml of solution and is supplied in 10 ml bottles.
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Telfast 120 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 120 mg of fexofenadine hydrochloride,
More informationP-RMS: FR/H/PSUR/0036/001
Core Safety Profile Active substance: Alprazolam Pharmaceutical form(s)/strength: Tablet uncoated, sugar coated, film coated, 0.25mg Tablet uncoated, 0.4 mg Tablet uncoated, sugar coated, film coated,
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi)
Core Safety Profile Active substance: Budesonide Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi) P - RMS: DK/H/PSUR/0041/001 Date of FAR:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Diclofenac Orifarm, 11.6 mg/g gel. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 gram Diclofenac Orifarm gel contains 11.6 mg (1.16%)
More informationInstil one or two drops in the conjunctival sac(s) every three to four hours as needed.
NEW ZEALAND DATA SHEET 1. PRODUCT NAME NAPHCON FORTE Eye Drops 0.1% 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Naphcon Forte contains naphazoline hydrochloride 1.0 mg in 1 ml (0.1%). Excipient with known
More informationNew Zealand Data Sheet
New Zealand Data Sheet POLARAMINE Tablets, film-coated dexchlorpheniramine maleate 2 mg Syrup - dexchlorpheniramine maleate 2 mg/5 ml (0.4 mg/ml) 1. Name of the Medicinal Product Polaramine (dexchlorpheniramine
More informationPRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets
PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets NAME OF THE MEDICINE Active Ingredients: Paracetamol and Codeine Phosphate Paracetamol: Molecular Formula: C 8 H
More informationPRODUCT INFORMATION ACTACODE
PRODUCT INFORMATION ACTACODE NAME OF THE MEDICINE Actacode codeine linctus contains codeine phosphate 5 mg/ml. Codeine phosphate is (5R,6S)-7,8-didehydro-4,5-epoxy-3-methoxy-N-methylmorphinan-6-ol dihydrogen
More informationRE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act
22 January 2019 RE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act Dear Healthcare Professional, This notification
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Anxiolytic and Hypnotic Drugs Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 OTHER ANXIOLYTIC AGENTS/ A. Antidepressants Many antidepressants are effective in the treatment
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklonova 500 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tranexamic acid 500 mg. For the full list of excipients,
More informationDexchlorpheniramine maleate (CAS no ) is described chemically as (+)-2-[pchloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine
PRODUCT INFORMATION NAME OF THE MEDICINE POLARAMINE (dexchlorpheniramine maleate) DESCRIPTION Polaramine (dexchlorpheniramine maleate) is the dextro-isomer of chlorpheniramine maleate. It is an antihistamine
More information